Claims
- 1. A method comprising administering an effective amount of apoptotic cells to a subject predisposed to an autoimmune disease before the clinical manifestation of a symptom associated with said autoimmune disease.
- 2. The method of claim 1, wherein said effective amount of apoptotic cells is administered to said subject after the identification of a disease marker for said autoimmune disease in said subject.
- 3. The method of claim 2, wherein said disease marker is selected from the group consisting of genetic marker, serological marker, immunological marker, gene expression profile, protein expression profile, and polymorphism.
- 4. The method of claim 1, wherein said predisposition is determined by the identification of a disease marker for said autoimmune disease in said subject.
- 5. The method of claim 4, wherein said disease marker is selected from the group consisting of genetic marker, serological marker, immunological marker, gene expression profile, protein expression profile, and polymorphism
- 6. The method of claim 1, wherein said effective amount of apoptotic cells is administered according to a dosage schedule selected from the group consisting of weekly, monthly, twice a month, three times a month, every other month, every three months, every six months, every nine months, and yearly.
- 7. The method of claim 1, wherein said apoptotic cells are in a liquid suspension.
- 8. The method of claim 7, wherein said apoptotic cells comprise from about 10% to about 90% of the total number of cells in said liquid suspension.
- 9. The method of claim 8, wherein said apoptotic cells comprise from about 30% to about 70% of the total number of cells in said liquid suspension.
- 10. The method of claim 1, wherein said apoptotic cells comprise apoptotic cells derived from a cultured cell line.
- 11. The method of claim 10, wherein said apoptotic cells comprise cultured cell line cells subjected to extracorporeal treatment.
- 12. The method of claim 11, wherein said extracorporeal treatment is selected from the group consisting of antibodies, chemotherapeutic agents, radiation, extracorporeal photopheresis, ultrasound, proteins, and oxidizing agents.
- 13. The method of claim 1, wherein said apoptotic cells comprise blood cells compatible with those of said subject.
- 14. The method of claim 13, wherein said apoptotic cells comprise blood cells subjected to extracorporeal treatment.
- 15. The method of claim 14, wherein said extracorporeal treatment is selected from the group consisting of antibodies, chemotherapeutic agents, radiation, extracorporeal photopheresis, ultrasound, proteins, and oxidizing agents.
- 16. The method of claim 13, wherein said blood cells comprise the subject's own blood cells.
- 17. The method of claim 13, wherein said blood cells comprise white blood cells that are compatible with that of said subject.
- 18. The method of claim 17, wherein said blood cells comprise the subject's own blood cells.
- 19. The method of claim 17, wherein said blood cells comprise T-cells.
- 20. The method of claim 19, wherein said blood cells comprise the subject's own blood cells.
- 21. The method of claim 1, wherein said effective amount of apoptotic cells comprises a dosage of apoptotic cells comprising from about 10,000 to about 10,000,000 apoptotic cells per kilogram body weight of said subject.
- 22. The method of claim 21, wherein said dosage contains from about 500,000 to about 5,000,000 apoptotic cells per kilogram body weight of said subject.
- 23. The method of claim 22, wherein said dosage contains from about 1,500,000 to about 4,000,000 apoptotic cells per kilogram body weight of said subject.
- 24. The method of claim 1, wherein said autoimmune disease is selected from the group consisting of alopecia areata, ankylosing spondylitis, antiphospholipid syndrome, autoimmune Addison's disease, autoimmune hemolytic anemia, autoimmune hepatitis, Beheet's disease, bullous pemphigoid, cardiomyopathy, celiac sprue-dermatitis, chronic fatigue immune dysfunction syndrome (CFIDS), chronic inflammatory demyelinating polyneuropathy, Churg-Strauss syndrome, cicatricial pemphigoid, CResT syndrome, cold agglutinin disease, Crohn's disease, discoid lupus, essential mixed cryoglobulinemia, fibromyalgia-fibromyositis, Graves' disease, Guillain-Barré, Hashimoto's thyroiditis, idiopathic pulmonary fibrosis, idiopathic thrombocytopenia purpura (ITP), IgA nephropathy, insulin dependent diabetes, juvenile arthritis, lichen planus, ménière's disease, mixed connective tissue disease, multiple sclerosis, myasthenia gravis, pemphigus vulgaris, pernicious anemia, polyarteritis nodosa, polychondritis, polyglandular syndromes, polymyalgia rheumatica, polymyositis and dermatomyositis, primary agammaglobulinemia, primary biliary cirrhosis, psoriasis, Raynaud's phenomenon, Reiter's syndrome, rheumatic fever, rheumatoid arthritis, sarcoidosis, scleroderma, Sjögren's syndrome, stiff-man syndrome, systematic lupus erythematosus, Takayasu arteritis, temporal arteritis/giant cell arteritis, ulcerative colitis, uveitis, vasculitis, vitiligo, and Wegener's granulomatosis.
- 25. A method comprising administering an effective amount of apoptotic cells to a subject predisposed to an atopic disease before the clinical manifestation of a symptom associated with said atopic disease
- 26. The method of claim 25, wherein said effective amount of apoptotic cells is administered to said subject after the identification of a disease marker for said atopic disease in said subject.
- 27. The method of claim 26, wherein said disease marker is selected from the group consisting of genetic marker, serological marker, immunological marker, gene expression profile, protein expression profile, and polymorphism.
- 28. The method of claim 25, wherein said predisposition is determined by the identification of a disease marker for said autoimmune disease in said subject.
- 29. The method of claim 28, wherein said disease marker is selected from the group consisting of genetic marker, serological marker, immunological marker, gene expression profile, protein expression profile, and polymorphism
- 30. The method of claim 25, wherein said effective amount of apoptotic cells is administered according to a dosage schedule selected from the group consisting of weekly, monthly, twice a month, three times a month, every other month, every three months, every six months, every nine months, and yearly.
- 31. The method of claim 25, wherein said apoptotic cells are in a liquid suspension.
- 32. The method of claim 31, wherein said apoptotic cells comprise from about 10% to about 90% of the total number of cells in said liquid suspension.
- 33. The method of claim 32, wherein said apoptotic cells comprise from about 30% to about 70% of the total number of cells in said liquid suspension.
- 34. The method of claim 25, wherein said apoptotic cells comprise apoptotic cells derived from a cultured cell line.
- 35. The method of claim 34, wherein said apoptotic cells comprise cultured cell line cells subjected to extracorporeal treatment.
- 36. The method of claim 35, wherein said extracorporeal treatment is selected from the group consisting of antibodies, chemotherapeutic agents, radiation, extracorporeal photopheresis, ultrasound, proteins, and oxidizing agents.
- 37. The method of claim 25, wherein said apoptotic cells comprise blood cells compatible with those of said subject.
- 38. The method of claim 37, wherein said apoptotic cells comprise blood cells subjected to extracorporeal treatment.
- 39. The method of claim 38, wherein said extracorporeal treatment is selected from the group consisting of antibodies, chemotherapeutic agents, radiation, extracorporeal photopheresis, ultrasound, proteins, and oxidizing agents.
- 40. The method of claim 37, wherein said blood cells comprise the subject's own blood cells.
- 41. The method of claim 37, wherein said blood cells comprise white blood cells that are compatible with that of said subject.
- 42. The method of claim 41, wherein said blood cells comprise the subject's own blood cells.
- 43. The method of claim 41, wherein said blood cells comprise T-cells.
- 44. The method of claim 43, wherein said blood cells comprise the subject's own blood cells.
- 45. The method of claim 25, wherein said effective amount of apoptotic cells comprises a dosage of apoptotic cells comprising from about 10,000 to about 10,000,000 apoptotic cells per kilogram body weight of said subject.
- 46. The method of claim 45, wherein said dosage contains from about 500,000 to about 5,000,000 apoptotic cells per kilogram body weight of said subject.
- 47. The method of claim 46, wherein said dosage contains from about 1,500,000 to about 4,000,000 apoptotic cells per kilogram body weight of said subject.
- 48. The method of claim 25, wherein said atopic disease is selected from the group consisting of atopic dermatitis, extrinsic bronchial asthma, urticaria, allergic rhinitis, and allergic enterogastritis.
- 49. A method comprising administering an effective amount of apoptotic cells to a subject predisposed to an autoimmune reaction manifested by a T-cell response before the clinical manifestation of a symptom associated with said autoimmune reaction.
- 50. The method of claim 49, wherein said effective amount of apoptotic cells is administered after the identification of a disease marker associated with said autoimmune reaction in said subject.
- 51. The method of claim 50, wherein said disease marker is selected from the group consisting of genetic marker, serological marker, immunological marker, gene expression profile, protein expression profile, and polymorphism.
- 52. The method of claim 49, wherein said predisposition is determined by the identification of a disease marker for said autoimmune reaction in said subject.
- 53. The method of claim 52, wherein said disease marker is selected from the group consisting of genetic marker, serological marker, immunological marker, gene expression profile, protein expression profile, and polymorphism
- 54. The method of claim 49, wherein said effective amount of apoptotic cells is administered according to a dosage schedule selected from the group consisting of weekly, monthly, twice a month, three times a month, every other month, every three months, every six months, every nine months, and yearly.
- 55. The method of claim 49, wherein said apoptotic cells are in a liquid suspension.
- 56. The method of claim 55, wherein said apoptotic cells comprise from about 10% to about 90% of the total number of cells in said liquid suspension.
- 57. The method of claim 56, wherein said apoptotic cells comprise from about 30% to about 70% of the total number of cells in said liquid suspension.
- 58. The method of claim 49, wherein said apoptotic cells comprise apoptotic cells derived from a cultured cell line.
- 59. The method of claim 58, wherein said apoptotic cells comprise cultured cell line cells subjected to extracorporeal treatment.
- 60. The method of claim 59, wherein said extracorporeal treatment is selected from the group consisting of antibodies, chemotherapeutic agents, radiation, extracorporeal photopheresis, ultrasound, proteins, and oxidizing agents.
- 61. The method of claim 49, wherein said apoptotic cells comprise blood cells compatible with those of said subject.
- 62. The method of claim 61, wherein said apoptotic cells comprise blood cells subjected to extracorporeal treatment.
- 63. The method of claim 62, wherein said extracorporeal treatment is selected from the group consisting of antibodies, chemotherapeutic agents, radiation, extracorporeal photopheresis, ultrasound, proteins, and oxidizing agents.
- 64. The method of claim 61, wherein said blood cells comprise the subject's own blood cells.
- 65. The method of claim 61, wherein said blood cells comprise white blood cells that are compatible with that of said subject.
- 66. The method of claim 65, wherein said blood cells comprise the subject's own blood cells.
- 67. The method of claim 65, wherein said blood cells comprise T-cells.
- 68. The method of claim 67, wherein said blood cells comprise the subject's own blood cells.
- 69. The method of claim 49, wherein said effective amount of apoptotic cells comprises a dosage of apoptotic cells comprising from about 10,000 to about 10,000,000 apoptotic cells per kilogram body weight of said subject.
- 70. The method of claim 69, wherein said dosage contains from about 500,000 to about 5,000,000 apoptotic cells per kilogram body weight of said subject.
- 71. The method of claim 70, wherein said dosage contains from about 1,500,000 to about 4,000,000 apoptotic cells per kilogram body weight of said subject.
- 72. The method of claim 49, wherein said autoimmune reaction is associated with a transplant selected from the group consisting of organ transplant, tissue transplant, bone marrow transplant, and stem cell transplant.
- 73. The method of claim 49, wherein said autoimmune reaction is associated with a disease selected from the group consisting of autoimmune disease and atopic disease.
- 74. A method comprising administering an effective amount of apoptotic cells to a transplant donor prior to harvesting said transplant from said donor.
- 75. The method of claim 74, wherein said effective amount of apoptotic cells is administered according to a dosage schedule selected from the group consisting of two days, one week prior to harvesting said transplant; three days, one week prior to harvesting said transplant; two days a week for two weeks prior to harvesting said transplant; and three days a week for three weeks prior to harvesting said transplant.
- 76. The method of claim 74, wherein said apoptotic cells are in a liquid suspension.
- 77. The method of claim 76, wherein said apoptotic cells comprise from about 10% to about 90% of the total number of cells in said liquid suspension.
- 78. The method of claim 77, wherein said apoptotic cells comprise from about 30% to about 70% of the total number of cells in said liquid suspension.
- 79. The method of claim 74, wherein said apoptotic cells comprise apoptotic cells derived from a cultured cell line.
- 80. The method of claim 79, wherein said apoptotic cells comprise cultured cell line cells subjected to extracorporeal treatment.
- 81. The method of claim 80, wherein said extracorporeal treatment is selected from the group consisting of antibodies, chemotherapeutic agents, radiation, extracorporeal photopheresis, ultrasound, proteins, and oxidizing agents.
- 82. The method of claim 74, wherein said apoptotic cells comprise blood cells compatible with those of said donor.
- 83. The method of claim 82, wherein said blood cells are subjected to extracorporeal treatment.
- 84. The method of claim 83, wherein said extracorporeal treatment is selected from the group consisting of antibodies, chemotherapeutic agents, radiation, extracorporeal photopheresis, ultrasound, proteins, and oxidizing agents.
- 85. The method of claim 82, wherein said blood cells comprise the donor's own blood cells.
- 86. The method of claim 82, wherein said blood cells comprise white blood cells that are compatible with that of said donor.
- 87. The method of claim 86, wherein said blood cells comprise the donor's own blood cells.
- 88. The method of claim 86, wherein said blood cells comprise T-cells.
- 89. The method of claim 88, wherein said blood cells comprise the donor's own blood cells.
- 90. The method of claim 74, wherein said effective amount of apoptotic cells comprises a dosage of apoptotic cells comprising from about 10,000 to about 10,000,000 apoptotic cells per kilogram body weight of said donor.
- 91. The method of claim 90, wherein said dosage contains from about 500,000 to about 5,000,000 apoptotic cells per kilogram body weight of said donor.
- 92. The method of claim 91, wherein said dosage contains from about 1,500,000 to about 4,000,000 apoptotic cells per kilogram body weight of said donor.
- 93. The method of claim 74, further comprising administering an effective amount of apoptotic cells to a recipient of said transplant prior to said recipient receiving said transplant.
- 94. The method of claim 93, wherein said effective amount of apoptotic cells is administered according to a dosage schedule selected from the group consisting of two days, one week prior to said recipient receiving said transplant; three days, one week prior to said recipient receiving said transplant; two days a week for two weeks prior to said recipient receiving said transplant; and three days a week for three weeks prior to said recipient receiving said transplant.
- 95. The method of claim 93, wherein said apoptotic cells are in a liquid suspension.
- 96. The method of claim 95, wherein said apoptotic cells comprise from about 10% to about 90% of the total number of cells in said liquid suspension.
- 97. The method of claim 96, wherein said apoptotic cells comprise from about 30% to about 70% of the total number of cells in said liquid suspension.
- 98. The method of claim 93, wherein said apoptotic cells comprise apoptotic cells derived from a cultured cell line.
- 99. The method of claim 98, wherein said blood cells are subjected to extracorporeal treatment.
- 100. The method of claim 99, wherein said extracorporeal treatment is selected from the group consisting of antibodies, chemotherapeutic agents, radiation, extracorporeal photopheresis, ultrasound, proteins, and oxidizing agents.
- 101. The method of claim 93, wherein said apoptotic cells comprise blood cells compatible with those of said recipient.
- 102. The method of claim 101, wherein said blood cells are subjected to extracorporeal treatment.
- 103. The method of claim 102, wherein said extracorporeal treatment is selected from the group consisting of antibodies, chemotherapeutic agents, radiation, extracorporeal photopheresis, ultrasound, proteins, and oxidizing agents.
- 104. The method of claim 101, wherein said blood cells comprise the recipient's own blood cells.
- 105. The method of claim 101, wherein said blood cells comprise white blood cells that are compatible with that of said recipient.
- 106. The method of claim 105, wherein said blood cells comprise the recipient's own blood cells.
- 107. The method of claim 105, wherein said blood cells comprise T-cells.
- 108. The method of claim 107, wherein said blood cells comprise the recipient's own blood cells.
- 109. The method of claim 93, wherein said effective amount of apoptotic cells comprises a dosage of apoptotic cells comprising from about 10,000 to about 10,000,000 apoptotic cells per kilogram body weight of said recipient.
- 110. The method of claim 109, wherein said dosage contains from about 500,000 to about 5,000,000 apoptotic cells per kilogram body weight of said recipient.
- 111. The method of claim 110, wherein said dosage contains from about 1,500,000 to about 4,000,000 apoptotic cells per kilogram body weight of said recipient.
- 112. The method of claim 93, further comprising the step of administering an effective amount of apoptotic cells to said recipient of said transplant after said recipient receives said transplant.
- 113. The method of claim 112, wherein said effective amount of apoptotic cells is administered according to a dosage schedule selected from the group consisting of weekly, monthly, twice a month, three times a month, every other month, every three months, every six months, every nine months, and yearly.
- 114. The method of claim 74, wherein said transplant is selected from the group consisting of organ, tissue, stem cell, and bone marrow.
- 115. The method of claim 114, wherein said organ transplant is an organ graft selected from the group consisting of syngeneic graft, allograft, and xenograft.
- 116. The method of claim 114, wherein said organ is selected from the group consisting heart, liver, pancreas, pancreatic islets, kidney, lung, larynx, stem cells, eyes, cornea, muscle, and skin.
- 117. The method of claim 114, wherein said organ is selected from the group consisting of human, artificial, clonal, and mammalian.
- 118. The method of claim 117, wherein said artificial organ is selected from the group consisting of heart, liver, pancreas, kidney, lung, pancreatic islets, larynx, blood, stem cells, eyes, cornea, muscle, and skin.
- 119. The method of claim 114, wherein said tissue transplant is a tissue graft selected from the group consisting of autograft, syngeneic graft, allograft, and xenograft.
- 120. The method of claim 114, wherein said tissue is selected from the group consisting of cartilage, bone, liver, small-bowel, neuronal, adrenal medullary tissue, fetal thymus tissue, and parathyroid tissue.
- 121. The method of claim 114, wherein said tissue is selected from the group consisting of human, artificial, clonal, and mammalian.
- 122. The method of claim 121, wherein said artificial tissue is selected from the group consisting of cartilage, bone, liver, small-bowel, neuronal, adrenal medullary tissue, fetal thymus tissue, and parathyroid tissue.
- 123. The method of claim 114, wherein said stem cell transplant is selected from the group consisting of allogeneic and xenogeneic.
- 124. The method of claim 114, wherein said stem cell is selected from the group consisting of ectoderm, endoderm, mesenchymal, or any cells derived therefrom.
- 125. The method of claim 114, wherein said bone marrow transplant is selected from the group consisting of allogeneic and xenogeneic.
- 126. A method comprising administering an effective amount of apoptotic cells to a recipient of a transplant prior to said recipient receiving said transplant.
- 127. The method of claim 126, wherein said effective amount of apoptotic cells is administered according to a dosage schedule selected from the group consisting of two days, one week prior to said recipient receiving said transplant; three days, one week prior to said recipient receiving said transplant; two days a week for two weeks prior to said recipient receiving said transplant; and three days a week for three weeks prior to said recipient receiving said transplant.
- 128. The method of claim 126, wherein said apoptotic cells are in a liquid suspension.
- 129. The method of claim 128, wherein said apoptotic cells comprise from about 10% to about 90% of the total number of cells in said liquid suspension.
- 130. The method of claim 129, wherein said apoptotic cells comprise from about 30% to about 70% of the total number of cells in said liquid suspension.
- 131. The method of claim 126, wherein said apoptotic cells comprise apoptotic cells derived from a cultured cell line.
- 132. The method of claim 131, wherein said apoptotic cells comprise cultured cell line cells subjected to extracorporeal treatment.
- 133. The method of claim 132, wherein said extracorporeal treatment is selected from the group consisting of antibodies, chemotherapeutic agents, radiation, extracorporeal photopheresis, ultrasound, proteins, and oxidizing agents.
- 134. The method of claim 126, wherein said apoptotic cells comprise blood cells compatible with those of said recipient.
- 135. The method of claim 134, wherein said blood cells are subjected to extracorporeal treatment.
- 136. The method of claim 135, wherein said extracorporeal treatment is selected from the group consisting of antibodies, chemotherapeutic agents, radiation, extracorporeal photopheresis, ultrasound, proteins, and oxidizing agents.
- 137. The method of claim 134, wherein said blood cells comprise the recipient's own blood cells.
- 138. The method of claim 134, wherein said blood cells comprise white blood cells that are compatible with that of said recipient.
- 139. The method of claim 138, wherein said blood cells comprise the recipient's own blood cells.
- 140. The method of claim 138, wherein said blood cells comprise T-cells.
- 141. The method of claim 140, wherein said blood cells comprise the recipient's own blood cells.
- 142. The method of claim 126, wherein said effective amount of apoptotic cells comprises a dosage of apoptotic cells comprising from about 10,000 to about 10,000,000 apoptotic cells per kilogram body weight of said recipient.
- 143. The method of claim 142, wherein said dosage contains from about 500,000 to about 5,000,000 apoptotic cells per kilogram body weight of said recipient.
- 144. The method of claim 143, wherein said dosage contains from about 1,500,000 to about 4,000,000 apoptotic cells per kilogram body weight of said recipient.
- 145. The method of claim 126, further comprising the step of administering an effective amount of apoptotic cells to said recipient of said transplant after said recipient receives said transplant.
- 146. The method of claim 145, wherein said effective amount of apoptotic cells is administered according to a dosage schedule selected from the group consisting of weekly, monthly, twice a month, three times a month, every other month, every three months, every six months, every nine months, and yearly.
- 147. The method of claim 126, wherein said transplant is selected from the group consisting of organ, tissue, and stem cell.
- 148. The method of claim 147, wherein said organ transplant is an organ graft selected from the group consisting of syngeneic graft, allograft, and xenograft.
- 149. The method of claim 147, wherein said organ is selected from the group consisting heart, liver, pancreas, pancreatic islets, kidney, lung, larynx, stem cells, eyes, cornea, muscle, and skin.
- 150. The method of claim 147, wherein said organ is selected from the group consisting of human, artificial, clonal, and mammalian.
- 151. The method of claim 150, wherein said artificial organ is selected from the group consisting of heart, liver, pancreas, kidney, lung, pancreatic islets, larynx, blood, stem cells, eyes, cornea, muscle, and skin.
- 152. The method of claim 147, wherein said tissue transplant is a tissue graft selected from the group consisting of autograft, syngeneic graft, allograft, and xenograft.
- 153. The method of claim 147, wherein said tissue is selected from the group consisting of cartilage, bone, liver, small-bowel, neuronal, adrenal medullary tissue, fetal thymus tissue, and parathyroid tissue.
- 154. The method of claim 147, wherein said tissue is selected from the group consisting of human, artificial, clonal, and mammalian.
- 155. The method of claim 154, wherein said artificial tissue is selected from the group consisting of cartilage, bone, liver, small-bowel, neuronal, adrenal medullary tissue, fetal thymus tissue, and parathyroid tissue.
- 156. The method of claim 147, wherein said stem cell transplant is selected from the group consisting of allogeneic and xenogeneic.
- 157. The method of claim 147, wherein said stem cell is selected from the group consisting of ectoderm, endoderm, mesenchymal, or any cells derived therefrom.
- 158. A method comprising administering an effective amount of apoptotic cells to a transplant donor prior to harvesting said transplant from said donor.
- 159. The method of claim 158, wherein said effective amount of apoptotic cells is administered according to a dosage schedule selected from the group consisting of two days, one week prior to harvesting said transplant; three days, one week prior to harvesting said transplant; two days a week for two weeks prior to harvesting said transplant; and three days a week for three weeks prior to harvesting said transplant.
- 160. The method of claim 158, wherein said apoptotic cells are in a liquid suspension.
- 161. The method of claim 160, wherein said apoptotic cells comprise from about 10% to about 90% of the total number of cells in said liquid suspension.
- 162. The method of claim 161, wherein said apoptotic cells comprise from about 30% to about 70% of the total number of cells in said liquid suspension.
- 163. The method of claim 158, wherein said apoptotic cells comprise apoptotic cells derived from a cultured cell line.
- 164. The method of claim 163, wherein said apoptotic cells comprise cultured cell line cells subjected to extracorporeal treatment.
- 165. The method of claim 164, wherein said extracorporeal treatment is selected from the group consisting of antibodies, chemotherapeutic agents, radiation, extracorporeal photopheresis, ultrasound, proteins, and oxidizing agents.
- 166. The method of claim 158, wherein said apoptotic cells comprise blood cells compatible with those of said donor.
- 167. The method of claim 166, wherein said apoptotic cells comprise blood cells subjected to extracorporeal treatment.
- 168. The method of claim 167, wherein said extracorporeal treatment is selected from the group consisting of antibodies, chemotherapeutic agents, radiation, extracorporeal photopheresis, ultrasound, proteins, and oxidizing agents.
- 169. The method of claim 166, wherein said blood cells comprise the donor's own blood cells.
- 170. The method of claim 166, wherein said blood cells comprise white blood cells that are compatible with that of said donor.
- 171. The method of claim 170, wherein said blood cells comprise the donor's own blood cells.
- 172. The method of claim 170, wherein said blood cells comprise T-cells.
- 173. The method of claim 172, wherein said blood cells comprise the donor's own blood cells.
- 174. The method of claim 158, wherein said effective amount of apoptotic cells comprises a dosage of apoptotic cells comprising from about 10,000 to about 10,000,000 apoptotic cells per kilogram body weight of said donor.
- 175. The method of claim 174, wherein said dosage contains from about 500,000 to about 5,000,000 apoptotic cells per kilogram body weight of said donor.
- 176. The method of claim 175, wherein said dosage contains from about 1,500,000 to about 4,000,000 apoptotic cells per kilogram body weight of said donor.
- 177. The method of claim 158, further comprising the step of administering an effective amount of apoptotic cells to a recipient of said transplant after said recipient receives said transplant.
- 178. The method of claim 177, wherein said effective amount of apoptotic cells is administered according to a dosage schedule selected from the group consisting of weekly, monthly, twice a month, three times a month, every other month, every three months, every six months, every nine months, and yearly.
- 179. The method of claim 158, wherein said transplant is selected from the group consisting of organ, tissue, stem cell, and bone marrow.
- 180. The method of claim 179, wherein said organ transplant is an organ graft selected from the group consisting of syngeneic graft, allograft, and xenograft.
- 181. The method of claim 179, wherein said organ is selected from the group consisting heart, liver, pancreas, pancreatic islets, kidney, lung, larynx, stem cells, eyes, cornea, muscle, and skin.
- 182. The method of claim 179, wherein said organ is selected from the group consisting of human, artificial, clonal, and mammalian.
- 183. The method of claim 182, wherein said artificial organ is selected from the group consisting of heart, liver, pancreas, kidney, lung, pancreatic islets, larynx, blood, stem cells, eyes, cornea, muscle, and skin.
- 184. The method of claim 179, wherein said tissue transplant is a tissue graft selected from the group consisting of autograft, syngeneic graft, allograft, and xenograft.
- 185. The method of claim 179, wherein said tissue is selected from the group consisting of cartilage, bone, liver, small-bowel, neuronal, adrenal medullary tissue, fetal thymus tissue, and parathyroid tissue.
- 186. The method of claim 179, wherein said tissue is selected from the group consisting of human, artificial, clonal, and mammalian.
- 187. The method of claim 186, wherein said artificial tissue is selected from the group consisting of cartilage, bone, liver, small-bowel, neuronal, adrenal medullary tissue, fetal thymus tissue, and parathyroid tissue.
- 188. The method of claim 179, wherein said stem cell transplant is selected from the group consisting of allogeneic and xenogeneic.
- 189. The method of claim 179, wherein said stem cell is selected from the group consisting of ectoderm, endoderm, mesenchymal, or any cells derived therefrom.
- 190. The method of claim 179, wherein said bone marrow transplant is selected from the group consisting of allogeneic and xenogeneic.
- 191. A method comprising administering an effective amount of apoptotic cells to a recipient of an implant prior to said recipient receiving said implant.
- 192. The method of claim 191, wherein said effective amount of apoptotic cells is administered according to a dosage schedule selected from the group consisting of two days, one week prior to said recipient receiving said implant; three days, one week prior to said recipient receiving said implant; two days a week for two weeks prior to said recipient receiving said implant; and three days a week for three weeks prior to said recipient receiving said implant.
- 193. The method of claim 191, wherein said apoptotic cells are in a liquid suspension.
- 194. The method of claim 193, wherein said apoptotic cells comprise from about 10% to about 90% of the total number of cells in said liquid suspension.
- 195. The method of claim 194, wherein said apoptotic cells comprise from about 30% to about 70% of the total number of cells in said liquid suspension.
- 196. The method of claim 191, wherein said apoptotic cells comprise apoptotic cells derived from a cultured cell line.
- 197. The method of claim 196, wherein said blood cells are subjected to extracorporeal treatment.
- 198. The method of claim 197, wherein said extracorporeal treatment is selected from the group consisting of antibodies, chemotherapeutic agents, radiation, extracorporeal photopheresis, ultrasound, proteins, and oxidizing agents.
- 199. The method of claim 191, wherein said apoptotic cells comprise blood cells compatible with those of said recipient.
- 200. The method of claim 199, wherein said blood cells are subjected to extracorporeal treatment.
- 201. The method of claim 200, wherein said extracorporeal treatment is selected from the group consisting of antibodies, chemotherapeutic agents, radiation, extracorporeal photopheresis, ultrasound, proteins, and oxidizing agents.
- 202. The method of claim 199, wherein said blood cells comprise the recipient's own blood cells.
- 203. The method of claim 199, wherein said blood cells comprise white blood cells that are compatible with that of said recipient.
- 204. The method of claim 203, wherein said blood cells comprise the recipient's own blood cells.
- 205. The method of claim 203, wherein said blood cells comprise T-cells.
- 206. The method of claim 205, wherein said blood cells comprise the recipient's own blood cells.
- 207. The method of claim 191, wherein said effective amount of apoptotic cells comprises a dosage of apoptotic cells comprising from about 10,000 to about 10,000,000 apoptotic cells per kilogram body weight of said recipient.
- 208. The method of claim 207, wherein said dosage contains from about 500,000 to about 5,000,000 apoptotic cells per kilogram body weight of said recipient.
- 209. The method of claim 208, wherein said dosage contains from about 1,500,000 to about 4,000,000 apoptotic cells per kilogram body weight of said recipient.
- 210. The method of claim 191, further comprising the step of administering an effective amount of apoptotic cells to said recipient of said implant after said recipient receives said implant.
- 211. The method of claim 210, wherein said effective amount of apoptotic cells is administered according to a dosage schedule selected from the group consisting of weekly, monthly, twice a month, three times a month, every other month, every three months, every six months, every nine months, and yearly.
- 212. The method of claim 191, wherein said implant is selected from the group consisting of spinal, vertebral, bone repair, bone replacement, joint replacement, metal plate, facial, hair, collagen, prostate seed, breast, hormonal, pacemaker, defibrillator, cochlear, muscle, and cortical.
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] The present application is related to and claims, under 35 U.S.C. §119(e), the benefit of U.S. Provisional Patent Application Serial No. 60/333,746, filed Nov. 29, 2001, which is entirely expressly incorporated herein by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60333746 |
Nov 2001 |
US |